CMS has policies that effect the use of Erythropoietin Stimulating Agents in ESRD facilities. To find out more, click on the links below.
Downloads | ESA Monitoring Policy, Effective October 1, 2006 [PDF, 151 KB] ESA Monitoring Policy, Effective April 1, 2006 [PDF, 173 KB] Medicare Benefit Policy Manual, Chapter 11, End Stage Renal Disease (ESRD) - Section 90 – Epoetin (EPO) [PDF, 347KB] Medicare Claims Processing Manual, Chapter 8 – Outpatient ESRD Hospital, Independent Facility and Physician/Supplier Claims - Section 60.4 – Epoetin Alfa (EPO) and Section 60.7 – Darbepoetin Alfa (Aranesp) for ESRD Patients [PDF, 625KB]
| Related Links Inside CMS | ESA Monitoring Policy, Effective January 1, 2008
ESA Cancer Policy -- NCD 000383
Coverage Center
Medicare Coverage Database | Related Links Outside CMS | | There are no Related Links Outside CMS
|
Page Last Modified: 06/09/2009 7:56:14 AM
Help with File Formats and Plug-Ins
Submit Feedback
|